Verato Enrich is powered by the company's cloud-based enterprise master person index. It can append a wide array of data ranging from basic contact information like missing phone numbers and addresses, to lifestyle data like income, ethnicity, race, occupation, and interests to patient records.
Approximately 80% of positive COVID-19 test results are submitted electronically and current reports show that as many as 50% lack enough contact data to support contact tracing.
With Verato Enrich, health systems, commercial labs, and public health teams gain an increased understanding of people and the critical non-clinical factors that impact health.
Enrich acts as an accelerator, enabling contact tracing and analysis to be more efficient and effective. Shortening the cycle between infection notification and actionable data is the only way to ensure a rapid response and contain the virus.
Verato Enrich extends the value proposition of Verato's next-generation EMPI, providing a critical infrastructure backbone for contact tracing and public health analytics, enabling health organisations to accurately integrate information from a range of sources and efficiently drive actionable workflows and information sharing.
Verato is the next generation of EMPI and patient matching.
As a HITRUST-certified EMPI, over 50 of the nation's most innovative healthcare organizations rely on Verato Referential Matching to manage and link person data quickly and at scale.
AbbVie declares quarterly dividend of USD1.73 per share
Alvotech and Lotus agree licensing deal for two biosimilar candidates
Quest Diagnostics declares quarterly dividend of of USD0.86 per share
BSF secures exclusive global commercialisation partnership for ETSYL
Saniona grants AstronauTx worldwide rights to neurological disease programme
Ridgetech reports financial results for fiscal year to March 2026
AMGEN announces Q3 2026 dividend
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones